Drugs that contain Vilazodone Hydrochloride
1. List of Viibryd drug patents
VIIBRYD Litigations
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7834020 | ALLERGAN | Polymorphic forms of 1-′4-(5-cyanoindol-3-yl)butyl-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride |
Jun, 2022
(9 months ago) | |
| US8673921 | ALLERGAN | Polymorphic forms of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride |
Jun, 2022
(9 months ago) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8236804 | ALLERGAN | Polymorphic forms of 1-′4-(5-cyanoindol-3-yl)butyl-4-(2-carbamoylbenzofuran-5-yl)piperazine hydrochloride |
Jun, 2022
(9 months ago) | |
| US8193195 | ALLERGAN | Polymorphic forms of 1-'4-(5-cyanoindol-3-yl) butyl-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride |
Jun, 2022
(9 months ago) | |
|
US7834020
(Pediatric) | ALLERGAN | Polymorphic forms of 1-′4-(5-cyanoindol-3-yl)butyl-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride |
Dec, 2022
(3 months ago) | |
|
US8193195
(Pediatric) | ALLERGAN | Polymorphic forms of 1-'4-(5-cyanoindol-3-yl) butyl-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride |
Dec, 2022
(3 months ago) | |
|
US8236804
(Pediatric) | ALLERGAN | Polymorphic forms of 1-′4-(5-cyanoindol-3-yl)butyl-4-(2-carbamoylbenzofuran-5-yl)piperazine hydrochloride |
Dec, 2022
(3 months ago) | |
|
US8673921
(Pediatric) | ALLERGAN | Polymorphic forms of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride |
Dec, 2022
(3 months ago) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| M (M) | Jan 31, 2023 |
| Pediatric Exclusivity (PED) | Jul 31, 2023 |
Market Authorisation Date: 21 January, 2011
Treatment: Treatment of major depressive disorder (mdd)
Dosage: TABLET;ORAL
How can I launch a generic of VIIBRYD before it's patent expiration?
More Information on Dosage
VIIBRYD family patents
16
Canada
15
United States
3
Japan
3
European Union
2
Slovakia
2
Hong Kong
2
Czech Republic
2
China
1
Israel
1
South Africa
1
Denmark
1
Austria
1
Mexico
1
Australia
1
Russia
1
Hungary
1
Germany
1
Argentina
1
Brazil
1
Portugal
1
Cyprus
1
Malaysia
1
Spain
1
Korea, Republic of
1
Poland
1
Ecuador
1
Ukraine
1
Estonia
1
New Zealand
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic